Vishwas Seshadri Sells 69,832 Shares of Abeona Therapeutics (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc. (NASDAQ:ABEO) CEO Vishwas Seshadri sold 69,832 shares of the firm’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $5.33, for a total transaction of $372,204.56. Following the transaction, the chief executive officer directly owned 1,460,408 shares of the company’s stock, valued at $7,783,974.64. The trade was a 4.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Vishwas Seshadri also recently made the following trade(s):

• On Monday, December 29th, Vishwas Seshadri sold 25,000 shares of Abeona Therapeutics stock. The stock was sold at an average price of $5.31, for a total transaction of $132,750.00.

Abeona Therapeutics Stock Down 3.7%

Shares of ABEO opened at $5.16 on Friday. The company has a quick ratio of 9.53, a current ratio of 9.74 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average price of $5.08 and a two-hundred day moving average price of $5.63. The stock has a market cap of $279.62 million, a price-to-earnings ratio of 4.20 and a beta of 1.12. Abeona Therapeutics Inc. has a 12 month low of $3.93 and a 12 month high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO) last issued its earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.17. Equities analysts predict that Abeona Therapeutics Inc. will post -1.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Abeona Therapeutics in a report on Wednesday. Wall Street Zen lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Abeona Therapeutics in a research note on Monday, October 13th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Abeona Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Institutional Investors Weigh In On Abeona Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Boone Capital Management LLC bought a new stake in shares of Abeona Therapeutics during the second quarter valued at approximately $7,126,000. AWM Investment Company Inc. acquired a new position in Abeona Therapeutics during the 2nd quarter worth $2,670,000. Y Intercept Hong Kong Ltd bought a new position in Abeona Therapeutics in the 2nd quarter valued at $581,000. Simplify Asset Management Inc. increased its stake in shares of Abeona Therapeutics by 36.7% in the 2nd quarter. Simplify Asset Management Inc. now owns 558,584 shares of the biopharmaceutical company’s stock valued at $3,173,000 after buying an additional 150,000 shares during the period. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Abeona Therapeutics during the second quarter worth $1,523,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.